Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
142.39B
Market cap142.39B
Price-Earnings ratio
17.71
Price-Earnings ratio17.71
Dividend yield
3.96%
Dividend yield3.96%
Average volume
11.08M
Average volume11.08M
High today
$65.66
High today$65.66
Low today
$63.53
Low today$63.53
Open price
$64.63
Open price$64.63
Volume
14.58M
Volume14.58M
52 Week high
$65.66
52 Week high$65.66
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $65.40, giving the company a market capitalization of 142.39B. It carries a P/E multiple of 17.71 and pays a dividend yield of 3.96%.

During the trading session on 2026-07-31, Bristol-Myers Squibb(BMY) shares reached a daily high of $65.66 and a low of $63.53. At a current price of $65.40, the stock is +2.9% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 14.58M, compared to an average daily volume of 11.08M.

The stock's 52-week range extends from a low of $42.52 to a high of $65.66.

The stock's 52-week range extends from a low of $42.52 to a high of $65.66.

BMY News

TipRanks 16h
Bristol-Myers Squibb: Strong Q2 Beat, Intact Pipeline Support Buy Rating as Jason Gerberry Raises Price Target from $66 to $71

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Bristol-Myers Squibb yesterday and set a price target of $71.00. Claim 55% Off TipR...

Nasdaq 1d
Bristol-Myers Squibb Q2 2026 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Bristol-Myers Squibb Q2 2026 Earnings Call Transcript
The Motley Fool 1d
Why Bristol Myers Squibb Stock Topped the Market on Thursday

Not for the first time this year, Bristol Myers Squibb (BMY +2.79%) posted an impressive quarterly earnings report Thursday morning. Investors clearly found muc...

Why Bristol Myers Squibb Stock Topped the Market on Thursday

Analyst ratings

61%

of 31 ratings
Buy
35.5%
Hold
61.3%
Sell
3.2%

More BMY News

Nasdaq 1d
Bristol Myers Squibb Shares Cross 4% Yield Mark

Looking at the universe of stocks we cover at Dividend Channel , in trading on Tuesday, shares of Bristol Myers Squibb Co. (Symbol: BMY) were yielding above the...

Bristol Myers Squibb Shares Cross 4% Yield Mark
Benzinga 1d
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength

• Bristol-Myers Squibb stock is showing upward movement. Why are BMY shares climbing? The U.S. large pharma company reported adjusted earnings of $2.04, beatin...

Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
TipRanks 1d
Bristol-Myers Squibb: Strong Quarter and Higher Eliquis Growth Outlook Offset by Legacy Declines and Pipeline Delays, Supporting Hold Rating

William Blair analyst Matt Phipps has maintained their neutral stance on BMY stock, giving a Hold rating on July 27. Unlock powerful investing tools with TipRa...

Simply Wall St 2d
Did Opdivo Combo Filing and AI-Driven R&D Expansion Just Shift Bristol-Myers Squibb's Investment Narrative?

In recent days, Bristol-Myers Squibb has drawn attention as analysts revised earnings expectations, a partner sought approval for an Opdivo combination therapy,...

Did Opdivo Combo Filing and AI-Driven R&D Expansion Just Shift Bristol-Myers Squibb's Investment Narrative?
Seeking Alpha 2d
Bristol-Myers Squibb Q3 Earnings Preview: Growth vs. legacy portfolio

Bristol-Myers Squibb (BMY) is projected to report a nearly 10% jump in its Q2 earnings when it reports its results on July 29, after the closing bell. Wall Str...

Bristol-Myers Squibb Q3 Earnings Preview: Growth vs. legacy portfolio
Benzinga 3d
How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings

Analysts expect the company to report quarterly earnings of $1.60 per share, up from $1.46 per share in the year-ago period. The consensus estimate for Bristol-...

How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 Earnings
Simply Wall St 3d
Bristol Myers Squibb Stock Still Looks Cheap After Fresh AI Drug Discovery News

Bristol-Myers Squibb stock has delivered a strong 42.2% return over the past year, while the current valuation checks show a mixed picture and the Discounted Ca...

Bristol Myers Squibb Stock Still Looks Cheap After Fresh AI Drug Discovery News

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.